This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer
Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data
by Zacks Equity Research
Earnings and other updates from bigwigs like Regeneron (REGN) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
The Zacks Analyst Blog Highlights: SPY, Devon Energy, NVIDIA, Moderna and Gartner
by Zacks Equity Research
The Zacks Analyst Blog Highlights: SPY, Devon Energy, NVIDIA, Moderna and Gartner
7 Stocks With Triple-Digit Gains Powering S&P 500 ETF
by Sweta Killa
The S&P 500 logged in eight consecutive gains, representing its longest winning streak since 2017, and closed above the 4,700 milestone for the first time ever.
Stock Market News for Nov 8, 2021
by Zacks Equity Research
Benchmarks closed higher on Friday lifted by solid October jobs report and encouraging COVID-19 antiviral drug results from Pfizer.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Novavax's (NVAX) Q3 Loss Widens, Revenues Lag Estimates
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss for the third quarter of 2021 while revenues miss estimates. Shares down.
Company News for Nov 5, 2021
by Zacks Equity Research
Companies In The News Are: MRNA, PH, PPL, QCOM.
Weekly Jobless Claims Drop Significantly
by Zacks Equity Research
Weekly Jobless Claims Drop Significantly.
Jobless Claims at New Post-Covid Lows, MRNA Misses by a Mile
by Mark Vickery
Initial Jobless Claims have now hit a new post-Covid low 269K -- down for the fifth straight week and closer to the 225K per week levels we'd seen prior to the pandemic.
Moderna (MRNA) Q3 Earnings Miss, COVID-19 Vaccine Brings $5B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine sales miss expectations. The company delivers 208 million doses of its COVID-19 vaccine during the third quarter. Stock declines in pre-market.
Moderna (MRNA) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of -14.06% and -17.81%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
5 ETFs Strategies to Play in November
by Sanghamitra Saha
November kicked off on a solid note after a solid October rally. Better-than-expected corporate earnings boosted the U.S. stocks.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is Direxion NASDAQ100 Equal Weighted Index Shares (QQQE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QQQE
Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q3 Earnings
by Zacks Equity Research
Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2022 on the third-quarter earnings call.
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales outlook for Moderna's (MRNA) authorized coronavirus vaccine on the third-quarter earnings call.
Moderna (MRNA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: JPMorgan, Shopify, PetroChina, Union Pacific, and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Shopify, PetroChina, Union Pacific, and Moderna
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $340.88, marking a -1.41% move from the previous day.
Top Analyst Reports for JPMorgan, Shopify & PetroChina
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Shopify Inc. (SHOP), and PetroChina Company Limited (PTR).
Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More
by Zacks Equity Research
Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB